Dhanuka Agritech Ltd

- No explicit mention of any current or future fundraising through debt or equity was made in the provided transcript. - The company has approved a buyback proposal of up to Rs. 70 crores at Rs. 1,400 per share, indicating strong confidence in cash flows and future growth, rather than raising capital. - An Employee Stock Option Plan (ESOP) has been introduced to enhance long-term alignment and support growth, but this is not a capital raise through issuance. - There is no discussion or indication of plans to raise funds via new debt or equity issuance in the Q&A or closing remarks.

- The company is focusing on building future-ready capabilities across manufacturing, R&D, and market development to support its next growth phase. - No specific current or future capex figures or strategic investments were detailed in the provided transcript. - There is mention of continued engagement with agricultural universities and scientific institutions for farmer education and technology dissemination, indicating ongoing investments in knowledge partnerships. - The management refers to labor shortages linked to several CapEx initiatives by government and private sectors, implying some industry-wide investments but without specifying Dhanuka's direct capex plans. - Investments include new product launches, such as biostimulants and active molecule manufacturing in India (for one Bayer-acquired molecule), suggesting capital deployment in production facilities. - The company made investments in entities like KisanKonnect, contributing to other income via valuation appreciation. No explicit detailed capex budget or future strategic capex commitments were disclosed.

- Company expects low double-digit growth in sales/revenue for FY '27. - Price growth is anticipated to be higher than volume growth, with volume growth lagging slightly. - Volume growth expected around 2% less than price growth. - Growth drivers include increased cotton, pulses, and oilseed acreages; soybean acreages are uncertain but could benefit from price increases. - Biostimulant portfolio expected to grow from Rs. 110 crores in FY '25 to over Rs. 130 crores in FY '27. - Bayer product revenues expected to almost double in FY '27 compared to FY '26. - Dahej facility revenue guidance downgraded to Rs. 75 crores (from Rs. 100 crores) for FY '27 but still 50% growth over FY '26. - Strategic focus on robust weedicide portfolio and upcoming launch of three biostimulant products in June to support growth.

- Management expects low double-digit revenue growth for FY '27, driven by price growth outpacing volume growth by about 2%. - EBIT/EBITDA margins may see a slight 100 bps decline due to loss of GST refund and reduced economic benefits, but gross margins are expected to be broadly maintained. - Other income is expected to rise due to appreciation in investments (e.g., KisanKonnect), supporting profitability. - New product launches, especially in biostimulants and herbicide portfolios (e.g., soybean-focused products), are expected to contribute to growth. - The inclusion of Bayer product revenues will partially impact growth in FY '27, with full contribution expected in FY '28. - Operational efficiencies, cost management, and smart sourcing are expected to sustain profit growth despite inflationary pressures. - Overall, management remains confident about strong earnings growth supported by market expansion, product launches, and stable margins.

The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited. However, some relevant insights related to demand and inventory are: - Q4 placement was similar to previous years; no significant pre-placement in the market. - Availability of technical materials/imports is not a challenge; supply is secured for Kharif season. - Herbicide consumption has just started; demand is somewhat mixed between actual demand and channel pull. - Strong sales and growth expected in Dahej unit with a revenue forecast of Rs. 75 crores for FY ’27, up 50% from FY ’26. - Growth anticipated in biostimulants and biological products with new product launches in June and expected revenue over Rs. 130 crores. - Management optimistic about robust Q1 performance driven by rainfall and increasing oilseed and pulse acreages. No explicit figure or detailed order book data was provided in the available content.